Net sales for the consolidated fiscal year ended March 31, 2025, amounted to 119,010 million yen (up 13.6% year on year). Operating income was 22,067 million yen (up 21.2% year on year), and ordinary income was 21,577 million yen (up 24.6% year on year). Profit attributable to owners of the parent was 10,780 million yen (up 24.6% year on year), which reflects impairment losses recognized by Taiyo Pharma Co., Ltd. following a review of sales rights with declining profitability.

Results by segment were as follows.
The Group consists of segments based on operating subsidiaries and comprises two reportable segments: the Electronics business and the Medical and Pharmaceuticals business.
Electronics
Due to increased sales volumes of rigid and PKG products and the depreciation of the yen, net sales in the Electronics totaled 81,703 million yen (up 14.4% year on year), an increase of 10,287 million yen from the previous fiscal year. Operating income was 21,458 million yen (up 30.4%), an increase of 5,002 million yen year on year.
During the period under review, the average exchange rate was 152.5 JPY per USD, representing a depreciation of 8.1 yen compared to the previous period’s average rate of 144.4 JPY per USD.

Medical and Pharmaceuticals
Due to the conversion of Ricc Co., Ltd. (currently mystarz Co., Ltd.) into a consolidated subsidiary, increased demand in the manufacturing and marketing business, and higher contract volumes in the contract manufacturing business, net sales in the Medical and Pharmaceuticala totaled 31,558 million yen (up 7.8% year on year), an increase of 2,288 million yen from the previous fiscal year. Operating income was 2,049 million yen (down 36.9%), a decrease of 1,199 million yen year on year.